| Clinical improvement of ankylosing spondylitis on switching tumor necrosis factor inhibitors: a case report |
|
Jae-Gun Lee, Hyun-Jin Park, Yeon-Ah Lee, Seung-Jae Hong, Sang-Hoon Lee, Hyung-In Yang |
|
|
| 증례 : 종양 괴사 인자 억제제 전환으로 호전된 강직성 척추염 1예 |
|
이재건.박현진.이연아.홍승재.이상훈.양형인, Hyun-Jin Park, Yeon-Ah Lee, Seung-Jae Hong, Sang-Hoon Lee, Hyung-In Yang |
|
|
|
|
|
|
| Abstract |
|
Ankylosing spondylitis is a seronegative multi-system inflammatory disorder affecting, primarily, the axial skeleton. Anti-tumor necrosis factor (TNF)-alpha agents promise better disease control for the treatment of ankylosing spondylitis resistant to classical disease-modifying treatment, and provide a better functional outcome. We present the case of a 20-year-old male diagnosed with ankylosing spondylitis. After two years of treatment with infliximab, the patient developed a clinical picture compatible with infliximab failure. We increased the dose of infliximab, but with no effect. Therefore, the infliximab therapy was halted, and the patient was treated with adalimumab. After 4 weeks, his symptoms improved, including his lower back stiffness, multiple arthralgia, and hip flexion contracture, and so did the laboratory findings. Based on this case, we review switching tumor necrosis factor inhibitors in ankylosing spondylitis. (Korean J Med 75:S930-S934, 2008) |
| Key Words:
Ankylosing spondylitis; Infliximab; Adalimumab |
|
PDF Links
Full text via DOI
Download Citation
